Surveillance of adverse drug events associated with tocilizumab in hospitalized veterans with coronavirus disease 2019 (COVID-19) to inform patient safety and pandemic preparedness
- Resource Type
- Article
- Authors
- Datta, Rupak; Barrett, Alexis; Burk, Muriel; Salone, Cedric; Au, Anthony; Cunningham, Francesca; Fisher, Ann; Dembry, Louise Marie; Akgün, Kathleen M.
- Source
- Infection Control & Hospital Epidemiology; October 2022, Vol. 43 Issue: 10 p1488-1491, 4p
- Subject
- Language
- ISSN
- 0899823X; 15596834
AbstractWe evaluated adverse drug events (ADEs) by chart review in a random national sample of 428 veterans with coronavirus disease 2019 (COVID-19) who received tocilizumab (n = 173 of 428). ADEs (median time, 5 days) occurred in 51 of 173 (29%) and included hepatoxicity (n = 29) and infection (n = 13). Concomitant medication discontinuation occurred in 22% of ADE patients; mortality was 39%.